ERBB2 and non-small cell lung carcinoma: HER2-directed therapy has recently become the standard of care for HER2-expressing unresectable or metastatic solid cancers, such as gastroesophageal junction and colorectal adenocarcinomas as well as non-small-cell lung cancer [7].